The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12

Investigational New Drugs

Volumn 28, Issue 4, 2010, Pages 445-453

  Roubalová, Eva ^a,c   Kvardová, Veronika ^a   Hrstka, Roman ^a   Bořilová, Šárka ^a   Michalová, Eva ^a   Dubská, Lenka ^a   Müller, Petr ^a   Sova, Petr ^b   Vojtěšek, Bořivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b Research and Development   (Czech Republic)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Apoptosis; Cisplatin; LA 12; p53; Transactivation; Tumor cells

Indexed keywords

(OC 6 43) BIS(ACETATO)(1 ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; LA 12; PLATINUM COMPLEX; PROTEIN BAX; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; AMANTADINE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BIS(ACETATO)(1 ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM(IV); BIS(ACETATO)(1-ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM(IV); CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; CELL CYCLE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

AMANTADINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MUTATION; ORGANOPLATINUM COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954309270     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9270-4     Document Type: Article

References (33)

1. Adams M, A'Hern RP, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM (1998) Chemotherapy for ovarian cancer-a consensus statement on standard practice. Br J Cancer 78:1404-1406
2. Zlatanova J, Yaneva J, Leuba SH (1998) Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 12:791-799
3. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, Brabec V (1992) Biophysical analysis of DNA modified by 1, 2-diaminocyclohexane platinum (II) complexes. Nucleic Acids Res 20:267-272. doi:10.1093/nar/20.2.267
4. Eastman A (1999) The mechanism of action of cisplatin: from adducts to apoptosis. In: Lippert B (ed) Cisplatin, chemistry, and biochemistry of a leading anticancer drug, 1st edn. Helvetica Chimica Acta, Zürich, pp 111-135
5. Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D, Neca J, Sindlerova L, Kozubik A (2004) Platinum (IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J Med Chem 47:761-763. doi:10.1021/jm030858+
6. Sova P, Chladek J, Zak F, Mistr A, Kroutil A, Semerad M, Slovak Z (2005) Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12. Int J Pharm 288:123-129 (OC-6-43)-bis (acetato) (1-adamantylamine) amminedichloroplatinum (IV). doi:10.1016/j.ijpharm. 2004.09.020 (Pubitemid 39656460)
7. Kozubik A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Zak F, Mistr A, Turanek J (2005) High effectiveness of platinum (IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 69:373-383. doi:10.1016/j.bcp. 2004.09.005
8. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072. doi:10.1101/gad.10.9.1054
9. Giaccia AJ, Kastan MB (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973-2983. doi:10.1101/gad.12.19. 2973
10. Jayaraman L, Prives C (1999) Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 55:76-87. doi:10.1007/s000180050271 (Pubitemid 29077856)
11. Meek DW (1998) New developments in the multi-site phosphorylation and integration of stress signalling at p53. Int J Radiat Biol 74:729-737. doi:10.1080/095530098141005
12. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation- acetylation cascade. Genes Dev 12:2831-2841. doi:10.1101/gad.12.18.2831
13. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825. doi:10.1016/0092-8674 (93) 90500-P
14. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y et al (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174
15. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclindependent kinase activities in human fibroblasts during radiationinduced G1 arrest. Cell 76:1013-1023. doi:10.1016/0092-8674 (94) 90379-4
16. Loignon M, Fetni R, Gordon AJ, Drobetsky EA (1997) A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. Cancer Res 57:3390-3394
17. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331. doi:10.1016/S0092-8674 (00) 81871-1
18. Lane DP (1994) p53 and human cancers. Br Med Bull 50:582-599
19. Blaydes JP, Hupp TR (1998) DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 17:1045-1052. doi:10.1038/sj.onc.1202014
20. Janicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357-9360. doi:10.1074/jbc.273.16.9357 (Pubitemid 28183012)
21. Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW (1992) Neuromedin B is present in lung cancer cell lines. Cancer Res 52:2732s-2736s
22. Shaulian E, Haviv I, Shaul Y, Oren M (1995) Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671-680
23. Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244. doi:10.1016/0022-1759 (92) 90122-A
24. Stephen CW, Helminen P, Lane DP (1995) Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol 248:58-78. doi:10.1006/jmbi.1995.0202
25. Fredersdorf S, Milne AW, Hall PA, Lu X (1996) Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 148:825-835
26. Sheard MA, Krammer PH, Zaloudik J (1999) Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br J Cancer 80:1689-1696. doi:10.1038/sj.bjc.6690585 (Pubitemid 29389620)
27. Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J (1997) Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer 73:757-762. doi:10.1002/(SICI) 1097-0215 (19971127) 73:5<757::AID-IJC24>3.0. CO;2-1
28. Brabec V (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 71:1-68. doi:10.1016/S0079-6603 (02) 71040-4
29. Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, Sova P, Zak F, Fahraeus R, Vojtesek B (2008) The novel platinum (IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anticancer Drugs 19:369-379. doi:10.1097/CAD.0b013e 3282f7f500
30. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4:793-805. doi:10.1038/nrc1455 (Pubitemid 39331151)
31. Jackel M, Kopf-Maier P (1991) Influence of cisplatin on cellcycle progression in xenografted human head and neck carcinomas. Cancer Chemother Pharmacol 27:464-471. doi:10.1007/BF00685161
32. Horvath V, Soucek K, Svihalkova-Sindlerova L, Vondracek J, Blanarova O, Hofmanova J, Sova P, Kozubik A (2007) Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum (IV) complex vs cisplatin. Invest New Drugs 5:435-443. doi:10.1007/s10637-007-9062-7 (Pubitemid 47224905)
33. Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Fedorocko P, Kozubik A (2006) Platinum (IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol 102:32-40. doi:10.1016/j.ygyno. 2005.11.016